Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. anti inflammatory drugs
Show results for
Products
Services
Training
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Anti Inflammatory Drugs Articles & Analysis: Older

13 news found

Influenza A Virus Mouse Models for Accelerated Research

Influenza A Virus Mouse Models for Accelerated Research

These mouse models of influenza A virus can also be used to evaluate different classes of therapeutic agents such as antivirals, anti-inflammatory drugs and pulmonary therapeutics, and to study viral pathogenesis and humoral responses in mice infected with influenza A virus. ...

ByCreative Diagnostics


Alfa Chemistry Enriches API Supply by Adding Lenalidomide, Parecoxib Sodium, and Rivaroxaban

Alfa Chemistry Enriches API Supply by Adding Lenalidomide, Parecoxib Sodium, and Rivaroxaban

Lenalidomide, as an oral immunomodulatory drug, revealed a good safety profile. Parecoxib Sodium Alfa Chemistry offers high-quality parecoxib sodium as API to support the amide prodrug of the cyclooxygenase II (COX-2)-selective inhibitor, non-steroidal anti-inflammatory drug (NSAID) valdecoxib, which has ...

ByAlfa Chemistry


Treatment of Prostatitis - What Forms of Medicines Released?

Treatment of Prostatitis - What Forms of Medicines Released?

Prostatitis is a disease characterized by the presence of inflammation and/or infection localized in the prostate gland. ...

ByProUroCare Medical Inc.


Healx receives IND and Orphan Drug Designation for fragile X clinical trial

Healx receives IND and Orphan Drug Designation for fragile X clinical trial

Healx has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of the compound HLX-0201 for Fragile X syndrome. The clinical study will attempt to find at least one novel and effective combination therapy for Fragile X syndrome - the world’s leading inherited cause of autism and learning difficulties which affects ...

ByHealx Ltd.


Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Lyra’s XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. The company’s current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for months following a single non-invasive, ...

ByLyra Therapeutics, Inc.


Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31

Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31

Lyra’s XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. The company’s current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for months following a single non-invasive, ...

ByLyra Therapeutics, Inc.


Billix, 14 billion Series A round closing

Billix, 14 billion Series A round closing

Bilix is a biotech company that develops bilirubin-based anti-inflammatory drugs, anti-cancer drug delivery systems (DDS), and contrast agents. ...

ByBilix Co., Ltd.


Neutralizing Antibody Development for SARS-CoV-2 Available at Creative Biolabs

Neutralizing Antibody Development for SARS-CoV-2 Available at Creative Biolabs

Drug discovery is often a laborious, and time-consuming task. Now, Creative Biolabs has optimized a portfolio of antiviral drug discovery services, especially neutralizing antibody development for SARS-CoV-2. ...

ByCreative Biolabs


Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain

Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain

(NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. ...

ByEli Lilly and Company


Investment attraction IR Bilirubin nano platform technology-based treatment Bilix

Investment attraction IR Bilirubin nano platform technology-based treatment Bilix

” succeeded in chemical synthesis of bilirubin for the first time in the world The nanoparticle itself: BRIXELLE-INFLA anti-inflammatory drug Nanoparticles + Hydrophobic Drugs: BRIXELLE-ONCO Anticancer Drug Delivery System Nanoparticles + SPION: BRIXELLE-SHINE Cancer Tumor Contrast Agent To see ...

ByBilix Co., Ltd.


tiakis (formerly Proteo Biotech AG) Elafin Enters the Clinic For Subcutaneous Use In Pulmonary Arterial Hypertension

tiakis (formerly Proteo Biotech AG) Elafin Enters the Clinic For Subcutaneous Use In Pulmonary Arterial Hypertension

tiakis BIOTECH AG today announced the start of the clinical development for the subcutaneous use of tiakis lead investigational drug candidate Elafin (INN: Tiprelestat). The Duke University Early Phase Research Unit initiated the recruitment of healthy individuals for the Phase I clinical trial in the U.S. to assess the safety and tolerability of repeated single doses of Elafin. ...

Bytiakis BIOTECH AG


tiakis receives GLP Certificate from Competent Authority

tiakis receives GLP Certificate from Competent Authority

About tiakis Elafin clinical development program tiakis biopharmaceutical drug candidate Elafin promises an excellent therapeutic benefit risk profile for the use as an anti-inflammatory and tissue protective drug. ...

Bytiakis BIOTECH AG


Symberix Awarded Multiple SBIR Grants from National Institutes of Health to Develop Proprietary Microbiome-Targeted Drugs

Symberix Awarded Multiple SBIR Grants from National Institutes of Health to Develop Proprietary Microbiome-Targeted Drugs

” Symberix has two initial programs in lead optimization for non-antibiotic, small molecules to address chemotherapy-induced diarrhea associated with the chemotherapeutic drug irinotecan, and lower GI toxicities caused by non-steroidal anti-inflammatory drugs (NSAIDs). ...

BySymberix, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT